Literature DB >> 18582147

Improving outcomes of elderly patients with community-acquired pneumonia.

Félix Gutiérrez1, Mar Masiá.   

Abstract

Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality in elderly patients. Therefore, efforts to optimize the healthcare process for patients with CAP are warranted. An organized approach to management is likely to improve clinical results. Assessing the severity of CAP is crucial to predicting outcome, deciding the site of care, and selecting appropriate empirical therapy. Unfortunately, current prognostic scoring systems for CAP such as CURB-65 (confusion, uraemia, respiratory rate, low blood pressure and 65 years of age) or the Pneumonia Severity Index have not been validated specifically in older adults, in whom assessment of mortality risk alone might not be adequate for predicting outcomes. Obtaining a microbial diagnosis remains problematic and may be particularly challenging in frail elderly persons, who may have greater difficulties producing sputum. Effective empirical treatment involves selection of a regimen with a spectrum of activity that includes the causative pathogen. Although most cases of CAP are probably caused by a single pathogen, dual and multiple infections are increasingly being reported. Streptococcus pneumoniae remains the overriding aetiological agent, particularly in very elderly people. However, respiratory viruses and 'atypical' organisms such as Chlamydia pneumoniae are being described with increasing frequency in old patients, and aspiration pneumonia should also be taken into consideration, particularly in very elderly subjects and those with dementia. Age >65 years is a well established risk factor for infection with drug-resistant S. pneumoniae. Clinicians should be aware of additional risk factors for acquiring less common pathogens or antibacterial-resistant organisms that may suggest that additions or modifications to the basic empirical regimen are warranted. In addition to administration of antibacterials, appropriate supportive therapy, covering management of severe sepsis and septic shock, respiratory failure, as well as management of any decompensated underlying disease, may be critical to improving outcomes in elderly patients with CAP. Immunization with pneumococcal and influenza vaccines has also been demonstrated to be beneficial in numerous large studies. There is good evidence that implementation of guidelines leads to improvement in clinical outcomes in elderly patients with CAP, including a reduction in mortality. Protocols should address a comprehensive set of elements in the process of care and should periodically be evaluated to measure their effects on clinically relevant outcomes. Assessment of functional clinical outcome variables, in addition to survival, is strongly recommended for this population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582147     DOI: 10.2165/00002512-200825070-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  216 in total

1.  Outbreak of Legionnaires' disease associated with a display whirlpool spa.

Authors:  D H Benkel; E M McClure; D Woolard; J V Rullan; G B Miller; S R Jenkins; J H Hershey; R F Benson; J M Pruckler; E W Brown; M S Kolczak; R L Hackler; B S Rouse; R F Breiman
Journal:  Int J Epidemiol       Date:  2000-12       Impact factor: 7.196

2.  Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA.

Authors:  Jürgen H Helbig; Søren A Uldum; P Christian Lück; Timothy G Harrison
Journal:  J Med Microbiol       Date:  2001-06       Impact factor: 2.472

3.  High-resolution computed tomography for the diagnosis of community-acquired pneumonia.

Authors:  H Syrjälä; M Broas; I Suramo; A Ojala; S Lähde
Journal:  Clin Infect Dis       Date:  1998-08       Impact factor: 9.079

4.  Sputum gram's stain in community-acquired pneumococcal pneumonia. A meta-analysis.

Authors:  W W Reed; G S Byrd; R H Gates; R S Howard; M J Weaver
Journal:  West J Med       Date:  1996-10

5.  What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia?

Authors:  E A Halm; G E Switzer; B S Mittman; M B Walsh; C C Chang; M J Fine
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

6.  Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors.

Authors:  E J Gorak; S M Yamada; J D Brown
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

7.  Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity.

Authors:  M Ruiz; S Ewig; M A Marcos; J A Martinez; F Arancibia; J Mensa; A Torres
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

8.  Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.

Authors:  Jared A Silverman; Lawrence I Mortin; Andrew D G Vanpraagh; Tongchuan Li; Jeff Alder
Journal:  J Infect Dis       Date:  2005-05-05       Impact factor: 5.226

9.  Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae.

Authors:  John R Lonks; Javier Garau; Lucía Gomez; Mariona Xercavins; Anna Ochoa de Echagüen; Ilana F Gareen; Philip T Reiss; Antone A Medeiros
Journal:  Clin Infect Dis       Date:  2002-08-09       Impact factor: 9.079

10.  Decreasing beta-lactam resistance in Pneumococci from the Memphis region: analysis of 2,152 isolates From 1996 to 2001.

Authors:  Grant W Waterer; Steven C Buckingham; Lori A Kessler; Michael W Quasney; Richard G Wunderink
Journal:  Chest       Date:  2003-08       Impact factor: 9.410

View more
  12 in total

1.  Severe pneumonia in the elderly: a multivariate analysis of risk factors.

Authors:  Wei Li; Cheng Ding; Shaojun Yin
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 2.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

3.  Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.

Authors:  J Majcher-Peszynska; M Loebermann; S Klammt; S Frimmel; R G Mundkowski; T Welte; E C Reisinger; B Drewelow
Journal:  Infection       Date:  2013-08-01       Impact factor: 3.553

4.  Poor clinical outcomes among pneumonia patients with depressive disorder.

Authors:  Li-Ting Kao; Shih-Ping Liu; Herng-Ching Lin; Hsin-Chien Lee; Ming-Chieh Tsai; Shiu-Dong Chung
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

5.  Enhanced inflammation in aged mice following infection with Streptococcus pneumoniae is associated with decreased IL-10 and augmented chemokine production.

Authors:  Andrew E Williams; Ricardo J José; Jeremy S Brown; Rachel C Chambers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-01-16       Impact factor: 5.464

6.  Psoriasis and the risk of pneumonia: a population-based study.

Authors:  Li-Ting Kao; Cha-Ze Lee; Shih-Ping Liu; Ming-Chieh Tsai; Herng-Ching Lin
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

7.  Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: A single-arm clinical trial.

Authors:  Mar Masiá; Sergio Padilla; Victoria Ortiz de la Tabla; Matilde González; Cristina Bas; Félix Gutiérrez
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

8.  Arginase 1: an unexpected mediator of pulmonary capillary barrier dysfunction in models of acute lung injury.

Authors:  Rudolf Lucas; Istvàn Czikora; Supriya Sridhar; Evgeny A Zemskov; Aluya Oseghale; Sebastian Circo; Stephen D Cederbaum; Trinad Chakraborty; David J Fulton; Robert W Caldwell; Maritza J Romero
Journal:  Front Immunol       Date:  2013-08-07       Impact factor: 7.561

9.  Comparative Outcome Analysis of Penicillin-Based Versus Fluoroquinolone-Based Antibiotic Therapy for Community-Acquired Pneumonia: A Nationwide Population-Based Cohort Study.

Authors:  Chi-Chuan Wang; Chia-Hui Lin; Kuan-Yin Lin; Yu-Chung Chuang; Wang-Huei Sheng
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

Review 10.  Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging.

Authors:  Catia Cillóniz; Diana Rodríguez-Hurtado; Antoni Torres
Journal:  Med Sci (Basel)       Date:  2018-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.